2.50
Hdl Handle:
http://hdl.handle.net/10547/224580
Title:
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Authors:
Smits, Evelien L.J.; Lee, Cindy; Hardwick, Nicola; Brooks, Suzanne E.; Van Tendeloo, Viggo F.I.; Orchard, Kim; Guinn, Barbara-Ann
Abstract:
Immunotherapy is currently under active investigation as an adjuvant therapy to improve the overall survival of patients with acute myeloid leukaemia (AML) by eliminating residual leukaemic cells following standard therapy. The graft-versus-leukaemia effect observed following allogeneic haematopoietic stem cell transplantation has already demonstrated the significant role of immune cells in controlling AML, paving the way to further exploitation of this effect in optimized immunotherapy protocols. In this review, we discuss the current state of cellular immunotherapy as adjuvant therapy for AML, with a particular focus on new strategies and recently published results of preclinical and clinical studies. Therapeutic vaccines that are being tested in AML include whole tumour cells as an autologous source of multiple leukaemia-associated antigens (LAA) and autologous dendritic cells loaded with LAA as effective antigen-presenting cells. Furthermore, adoptive transfer of cytotoxic T cells or natural killer cells is under active investigation. Results from phase I and II trials are promising and support further investigation into the potential of cellular immunotherapeutic strategies to prevent or fight relapse in AML patients.
Affiliation:
Laboratory of Experimental Haematology, Vaccine and Infectious Disease Institute, Antwerp University Hospital, University of Antwerp, Wilrijkstraat 10, 2650, Antwerp, Belgium. evelien.smits@uza.be
Citation:
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. 2011, 60 (6):757-69 Cancer Immunol. Immunother.
Publisher:
SpringerLink
Journal:
Cancer immunology, immunotherapy : CII
Issue Date:
Jun-2011
URI:
http://hdl.handle.net/10547/224580
DOI:
10.1007/s00262-011-1022-6
PubMed ID:
21519825
Additional Links:
http://www.springerlink.com/content/r12815u123n7x320/?MUD=MP
Type:
Article
Language:
en
ISSN:
1432-0851
Sponsors:
Leukaemia and Lymphoma Research, Cancer Research U.K.
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorSmits, Evelien L.J.en_GB
dc.contributor.authorLee, Cindyen_GB
dc.contributor.authorHardwick, Nicolaen_GB
dc.contributor.authorBrooks, Suzanne E.en_GB
dc.contributor.authorVan Tendeloo, Viggo F.I.en_GB
dc.contributor.authorOrchard, Kimen_GB
dc.contributor.authorGuinn, Barbara-Annen_GB
dc.date.accessioned2012-05-18T10:44:52Z-
dc.date.available2012-05-18T10:44:52Z-
dc.date.issued2011-06-
dc.identifier.citationClinical evaluation of cellular immunotherapy in acute myeloid leukaemia. 2011, 60 (6):757-69 Cancer Immunol. Immunother.en_GB
dc.identifier.issn1432-0851-
dc.identifier.pmid21519825-
dc.identifier.doi10.1007/s00262-011-1022-6-
dc.identifier.urihttp://hdl.handle.net/10547/224580-
dc.description.abstractImmunotherapy is currently under active investigation as an adjuvant therapy to improve the overall survival of patients with acute myeloid leukaemia (AML) by eliminating residual leukaemic cells following standard therapy. The graft-versus-leukaemia effect observed following allogeneic haematopoietic stem cell transplantation has already demonstrated the significant role of immune cells in controlling AML, paving the way to further exploitation of this effect in optimized immunotherapy protocols. In this review, we discuss the current state of cellular immunotherapy as adjuvant therapy for AML, with a particular focus on new strategies and recently published results of preclinical and clinical studies. Therapeutic vaccines that are being tested in AML include whole tumour cells as an autologous source of multiple leukaemia-associated antigens (LAA) and autologous dendritic cells loaded with LAA as effective antigen-presenting cells. Furthermore, adoptive transfer of cytotoxic T cells or natural killer cells is under active investigation. Results from phase I and II trials are promising and support further investigation into the potential of cellular immunotherapeutic strategies to prevent or fight relapse in AML patients.en_GB
dc.description.sponsorshipLeukaemia and Lymphoma Research, Cancer Research U.K.en_GB
dc.language.isoenen
dc.publisherSpringerLinken_GB
dc.relation.urlhttp://www.springerlink.com/content/r12815u123n7x320/?MUD=MPen_GB
dc.rightsArchived with thanks to Cancer immunology, immunotherapy : CIIen_GB
dc.subjectacute myeloid leukaemiaen_GB
dc.subjectclinical immunotherapyen_GB
dc.subjectclinical trialsen_GB
dc.subject.meshHumans-
dc.subject.meshImmunotherapy, Adoptive-
dc.subject.meshLeukemia, Myeloid, Acute-
dc.titleClinical evaluation of cellular immunotherapy in acute myeloid leukaemia.en
dc.typeArticleen
dc.contributor.departmentLaboratory of Experimental Haematology, Vaccine and Infectious Disease Institute, Antwerp University Hospital, University of Antwerp, Wilrijkstraat 10, 2650, Antwerp, Belgium. evelien.smits@uza.been_GB
dc.identifier.journalCancer immunology, immunotherapy : CIIen_GB

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.